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Abstract
Background: Alendronate has been found to reduce the risk of fractures in postmenopausal women as
demonstrated in multiple randomized controlled trials enrolling thousands of women. Yet there is a
paucity of such randomized controlled trials in osteoporotic men. Our objective was to systematically
review the anti-fracture efficacy of alendronate in men with low bone mass or with a history of prevalent
fracture(s) and incorporate prior knowledge of alendronate efficacy in women in the analysis.
Methods: We examined randomized controlled trials in men comparing the anti-fracture efficacy of
alendronate to placebo or calcium or vitamin D, or any combination of these. Studies of men with
secondary causes of osteoporosis other than hypogonadism were excluded. We searched the following
electronic databases (without language restrictions) for potentially relevant citations: Medline, Medline in
Process (1966-May 24/2004), and Embase (1996–2004). We also contacted the manufacturer of the drug
in search of other relevant trials. Two reviewers independently identified two trials (including 375 men),
which met all inclusion criteria. Data were abstracted by one reviewer and checked by another. Results
of the male trials were pooled using Bayesian random effects models, incorporating prior information of
anti-fracture efficacy from meta-analyses of women.
Results: The odds ratios of incident fractures in men (with 95% credibility intervals) with alendronate (10
mg daily) were: vertebral fractures, 0.44 (0.23, 0.83) and non-vertebral fractures, 0.60 (0.29, 1.44).
Conclusion: In conclusion, alendronate decreases the risk of vertebral fractures in men at risk. There is
currently insufficient evidence of a statistically significant reduction of non-vertebral fractures, but the
paucity of trials in men limit the statistical power to detect such an effect.
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Background
Osteoporosis increases the risk of fragility fracture in both
genders. In a population-based study of Canadians age 50
years by the Canadian Multicenter Osteoporosis Study
Group, the prevalence of vertebral fractures was found to
be 23.5% in men and 21.5% in women [1]. Alendronate,
a potent oral bisphosphonate, decreases the risk of frac-
tures in postmenopausal women with low bone mass or
prevalent fractures, as established in a recent meta-analy-
ses examining outcomes in thousands of women [2-4].
Less is known about the effect of alendronate in men, due
to a paucity of randomized controlled trials. However,
osteoporotic fractures are common in aging men; in fact
the lifetime risk of a fracture of the spine, hip or distal
radius is 13% for white men older than 50 years [5]. Our
objective was to determine whether alendronate decreases
risk of vertebral and non-vertebral fractures in men.
Upon initiating our review, we were aware of the paucity
of trials examining anti-fracture efficacy of bisphospho-
nates in men. However, given that bisphosphonates
decrease osteoclastic resorption in a mechanism inde-
pendent of sex steroid status [6], we believed that the
effect of alendronate in men would be similar to that pre-
viously observed in women. Therefore, the anti-fracture
efficacy of alendronate in women would be relevant prior
information to be incorporated in assessing treatment
effects in men. Classical, frequentist, statistical methods
do not offer the flexibility to incorporate relevant prior
knowledge or beliefs in analysis of data, thus we sought an
alternative statistical approach to analyze the results of
our systematic review and we turned to Bayesian methods.
Bayesian statistical methods can explicitly and quantita-
tively incorporate relevant prior evidence in health tech-
nology assessment [7]. The foundation of Bayesian
statistical methodology is Bayes' theorem, which is "a for-
mula that shows how existing beliefs, formally expressed
as probability distributions, are modified by new infor-
mation" [8]. In Bayesian methodology, the conclusions of
the analysis (known as the "posterior" inferences) are a
result of modification of the "prior" data (in this case,
known anti-fracture efficacy of alendronate in post-meno-
pausal women), by new data collected (known as the
"likelihood function", in this case, the data collected in
men) [9]. Bayesian methodology is similar to clinical
practice, as typically a clinician has a strong "prior" belief
of, for example, a diagnosis such as osteoporosis prior to
diagnostic testing, based on the clinical profile of the
patient (such as age, gender, risk factors) and the results of
diagnostic testing (analogous to a "likelihood function"),
are used to confirm or refute those clinical suspicions and
formulate a final conclusion (analogous to a "posterior"
inference). Thus, Bayesian approaches are clinically intui-
tive. Moreover, results of Bayesian analyses are also more
easily clinically translated than those of frequentist analy-
ses [8]. For example, a Bayesian result tells us how likely
is the result (such as an odds ratio), given the data [8]; as
opposed to a frequentist result, which tell us how likely
are the data given the null hypothesis. For these reasons,
Bayesian methodology may be incorporated in healthcare
medical decision-making [9]. Justification for the use of
Bayesian approach in this study is the ability to directly
answer the clinically relevant question: how likely is an
osteoporotic man treated with alendronate to be pro-
tected from fracture given the current evidence in men and
prior evidence in women? A classical frequentist analysis
does not allow the flexibility to incorporate prior relevant
information in the analysis and all relevant data from
women would be ignored in such an analysis. Thus, a
Bayesian approach was chosen as the primary analysis
method for our study.
Methods
Design of the systematic review, inclusion and exclusion 
criteria
A systematic review of randomized-controlled trials was
performed to determine the efficacy of alendronate (≥  5
mg daily) in preventing vertebral and non-vertebral frac-
tures in adult men with low bone mass or prevalent frac-
ture(s). As a requirement for inclusion for each study, at
least half the study population was required to consist of
men, and the required minimum trial follow-up period
was one year. A control group could be treated with cal-
cium or vitamin D (any formulation, any dose), but no
other active anti-osteoporotic therapies. In the case of
duplicate publications on the same study population,
only the study with the largest population size and longest
follow-up period was included in our review. Studies were
excluded if fracture outcome data were not provided, or if
they included patients with bone or mineral disorders
other than primary osteoporosis, with the exception of
osteoporosis secondary to hypogonadism. Our focus was
primarily on intention-to-treat data as such analyses are
thought to avoid selection bias [10].
Data sources and abstraction
One author searched the following electronic databases
(without language restrictions): Medline, Medline-in-
Process (1966-May 24/2004), Embase (1996–2004), and
the Cochrane Central Register of Controlled Trials (1800
to May, 2004). The search terms used included the text-
words "alendronate" or "fosamax", and the search was
restricted to articles pertaining to adult male humans (age
≥  19 years), clinical trials, controlled clinical trials, and
randomized controlled trials (textwords "male" or "men"
added in Embase) (Appendix). All citations were reviewed
by two co-authors and citations which were deemed
potentially relevant by either reviewer were examined in
full by both investigators. Consensus was reached by bothBMC Musculoskeletal Disorders 2005, 6:39 http://www.biomedcentral.com/1471-2474/6/39
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reviewers on all included studies. One co-author per-
formed a PubMed search on the primary author of each
included study to look for updated information on the
included trials (such as updated follow-up data) or addi-
tional relevant trials and this search was restricted to stud-
ies including the text word "alendronate" or "fosamax"
(up to May 24, 2004). The co-author who performed this
secondary search examined the retrieved references and
reviewed any potentially relevant trials with a second
investigator. Consensus was again reached by both
reviewers on whether any trial updates or new trials would
be included. Merck-Frosst representatives at the Canadian
and world-wide headquarters were contacted for informa-
tion on any other potentially relevant trials not found by
the electronic search. Male trial data were abstracted by
one co-author and was checked by another. Fracture out-
comes of individual trials in men were summarized using
an intention-to-treat analysis principle. For randomized
controlled trials meeting inclusion criteria in which frac-
ture data were not published, primary authors were con-
tacted by electronic mail for supplemental information.
Statistical analyses and assumptions
The Bayesian approach was chosen because it allows for-
mal incorporation of prior information in the analysis [7].
Bayesian random effects models predicting the log odds
of vertebral fracture and non-vertebral fracture in alendr-
onate-treated men incorporated prior information from
published meta-analyses in postmenopausal women [2].
The effect of alendronate on fracture outcomes was
assumed to be similar in both genders. In estimating the
priors, we noted that in published random effects meta-
analyses of postmenopausal women, the relative risk of
vertebral fracture with alendronate therapy (≥  5 mg daily)
was 0.52 (95% confidence intervals [CI], 0.43, 0.65)
(9360 women in eight studies); whereas the relative risk
of non-vertebral fracture (alendronate ≥  10 mg daily) was
0.51 (95% CI, 0.38, 0.69) (3723 women in six studies)
[2]. For the purpose of our analyses, each relative risk was
assumed to approach an odds ratio (OR), based on the
assumption that relative risks and odds ratios are similar
if the risk of the disease is very small, which was the case
given the large sample sizes and low event rates. For each
prior we assumed the normal distribution on log (OR)
scale. Thus, the mean log OR was assumed to be -0.65
with variance 0.19 (precision 5.2) for vertebral fractures
and -0.67 with variance 0.24 (precision 4.1) for non-ver-
tebral fractures, respectively for alendronate-treated
women. For the study heterogeneity, we assumed a
Gamma prior distribution, determined on the basis that
the mean heterogeneity between k studies is expected to
be equal to the degrees of freedom, k-1 [21]. Thus, in cal-
culating priors for study heterogeneity, we determined
that a = 3.5 and b = 0.5 with k-1 = 7 for the analysis of ver-
tebral fracture data; furthermore, a = 2.5 and b = 0.5 with
k-1 = 5 for the analysis of non-vertebral fracture data.
WinBUGS version 1.4 (MRC Biostatistics Unit, Cam-
bridge, UK) was used for all Bayesian statistical analyses.
The prior knowledge of treatment effects of alendronate in
women ("prior distribution") was incorporated in a hier-
archical model and then the "likelihood function" of data
in men was incorporated in this model for the same out-
come. In order to transform the "prior" and "likelihood
function" data to a "posterior" inference (final result),
simulations were performed using Markov chain Monte
Carlo Methods [9]. For each outcome, we performed
20,000 simulations, with Gibbs sampling of results for
posterior distributions started at 2,500, after convergence
was achieved in all models. A posterior distribution of the
treatment effect of the results of alendronate on the log
(OR) and inverse log (OR) scales was obtained for the
outcomes of vertebral and non-vertebral fractures, respec-
tively. The results were expressed as the posterior mean
with corresponding 95% credibility interval [CRI]) on the
inverse log (OR) scale (the latter interpreted as analogous
to the OR). Using the traditional definition of 95% credi-
bility interval, there is a 95% probability that the true
treatment effect, in this case, the odds ratio, lies within
this interval [20]. Comparison of the Bayesian results with
the classical or frequentist random effects results using
Review manager 4.1 (Cochrane Collaboration, Oxford,
UK) was performed. The frequentist analysis did not
incorporate any prior assumptions based on anti-fracture
efficacy of alendronate in women and odds ratios of treat-
ment effects were expressed as OR with the corresponding
95% confidence interval (CI).
Results
Results of search for relevant studies
We obtained 103 unique references from our primary
electronic searches of Medline/Medline-in-Process and
Embase; no additional unique references were found
using the Cochrane Central Register of Controlled Trials.
No additional studies were revealed by Merck-Frosst. An
additional six unique citations were examined upon
searching under the name of the primary author of
included trials. Nine of the references retrieved by our
electronic searches were considered potentially relevant
and reviewed in full-text form by two authors [11-19].
Only studies by Orwoll et al. [11] and Ringe et al. [12]
(with information on numbers of patients with vertebral
fractures from Orwoll documented in a subsequent paper
[13]), met all inclusion criteria. The following studies,
were excluded after review of full-text for the following
reasons: Ringe 2002 (overlap of included study) [14],
Gonnelli 2003 (lack of fracture outcomes, no additional
information provided after attempting to contact primary
author by electronic mail) [15], Finkelstein 2003 (activeBMC Musculoskeletal Disorders 2005, 6:39 http://www.biomedcentral.com/1471-2474/6/39
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control of parathyroid hormone) [16], van der Poest 2002
(study of bone density changes in the setting of acute
lower extremity fracture with immobilization) [17], Kush-
ida 2002 (men comprised only 4% of the study popula-
tion) [18], Ho 2000 (lack of control group) [19]. Details
of the process of exclusion of trials are shown in Figure 1.
Summary of alendronate trials in men
Characteristics of the included randomized controlled
studies in men are shown in Table 1. Hypogonadal men
were included in the Orwoll study [11] but not the Ringe
study [12]. Approximately half of the men in each study
had a history of one or more prevalent vertebral fractures
before enrollment in the trial [11,12]. In the Orwoll study,
an incident vertebral fracture was defined using the semi-
quantitative method of Genant [22], as assessed by a radi-
ologist blinded to treatment assignment at the University
of California in San Francisco [11]. In the Ringe study, a
vertebral fracture was defined by a new decrease in verte-
bral height of at least 20%, as assessed by a radiologist
blinded to treatment assignment [12]. The Orwoll study
was two years in duration [11], whereas the Ringe study
extended for three years [12]. In both trials, the active
treatment group received 10 mg of alendronate as well as
500 mg supplemental calcium orally daily [11,12]. In the
Orwoll study, men in the treatment and control group
Process of exclusion of studies Figure 1
Process of exclusion of studies. The trials included at the final step are 1) Orwoll E et al. Alendronate for the treat-
ment of osteoporosis in men. N Engl J Med 2000;343(9):604-10; and 2) Ringe JD., et al. Alendronate treatment of 
established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. Rheuma-
tol Int 2004;24(2):110-3; with supplemental information on the Orwoll trial obtained from the review article, 3) Ringe JD, 
Orwoll E, et al. Treatment of male osteoporosis: recent advances with alendronate. Osteoporos Int 2002; 13(3):195-9. 
The two-year analysis of the Ringe trial was excluded because of overlap of patients with the 3-year analysis: Ringe JD, et al. 
Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. J Clin 
Endocrinol Metab 2001;86(11):5252–5255.BMC Musculoskeletal Disorders 2005, 6:39 http://www.biomedcentral.com/1471-2474/6/39
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received 400–450 IU vitamin D daily [11], whereas in the
Ringe study, only men in the control arm received
supplemental vitamin D in the form of 1 µg alfacalcidiol
daily [12].
In the Orwoll study, 4/146 alendronate-treated (2.7%)
and 7/95 placebo-treated (7.4%) men sustained a verte-
bral fracture at two years [11,13]. In the Ringe study, 7/68
alendronate-treated men (10.3%) and 16/66 (24.2%)
control participants sustained a vertebral fracture at three
years [12]. Furthermore, In the Orwoll study, 6/146 alen-
dronate-treated men (4.1%) and 5/95 men (5.3%) pla-
cebo-treated men sustained a non-vertebral fracture [11].
In the Ringe study, 6/68 men (8.8%) alendronate-treated
men and 8/66 (12.1%) control participants sustained a
non-vertebral fracture [12].
Results of pooled analyses
Upon incorporating the prior information from postmen-
opausal women with the male data in the Bayesian ran-
dom effects model, the OR of vertebral fracture in
alendronate-treated men was 0.44 (95% CRI 0.23, 0.83)
and the OR of non-vertebral fracture was 0.60 (95% CRI
0.29, 1.44). Similar results were found using the frequen-
tist random effects models of male data (vertebral fracture
OR 0.36, 95% CI 0.17, 0.77; non-vertebral fracture OR
0.73, 95% CI, 0.32, 1.67), without incorporation of any of
the data from women (Figure 2).
Discussion
Limitations of our systematic review include the paucity
of trial data from men, the small sample sizes in trials, the
variations in trial duration between studies, and the
inconsistency of calcium and vitamin D formulations
between trials (with the possibility that the alfacalcidiol
used in the Ringe study could be considered a form of
active therapy [23]). We were also unable to perform a per
protocol sensitivity analysis of the anti-fracture efficacy of
alendronate in men who were compliant with therapy as
these data were not published in the primary trials. We
did not include unpublished data. We also did not contact
author to clarify details of the randomization procedures.
Merits of our study include its systematic nature, includ-
ing both Bayesian and traditional frequentist analyses of
available data, and the examination of clinically relevant
fracture outcomes. Of note, the numerical estimates of
odds ratios and their respective credibility or confidence
intervals were similar using Bayesian and frequentist anal-
yses in this study. These findings are not surprising, given
that the treatment effects of alendronate in women, from
Table 1: Characteristics of included studies
Study 
(reference)
Sample (ALN*/ 
control) and 
duration
Inclusion 
criteria
Age (years) 
(SD‡) 
Percentage 
prevalent 
vertebral 
fractures (VF, 
%)
Intervention/ 
Control
Blinding, 
randomization
Loss to follow-
up or withdrew 
from study (n/
N) (%)
Orwoll 2000 
[11]
146/95 (2 years) Men with BMD† 
T-score = -2 at 
femoral neck and 
T-score = -1 at the 
lumbar spine;
OR Men with T-
score = -1 at the 
femoral neck and 
at least one 
vertebral or 
osteoporotic 
fracture
ALN:
Mean age 63 (13)
49% VF
Control: Mean age 
63 (12)
52% VF
ALN*: 10 mg + 
500 mg Calcium + 
400–450 IU 
Vitamin D
Control: 500 mg 
Calcium + 400–
450 IU Vitamin D
- Double-blind
- Radiologists 
reading vertebral 
x-rays blinded to 
intervention
-Method of 
randomization 
unclear
38/241 (15.8%)
Ringe 2004 [12] 68/66 (3 years) Men with BMD† 
T-score = -2.5 at 
femoral neck or 
lumbar spine, 
excluding 
hypogonadal men
ALN*:
Mean age 52.7 
(11.1)
54% VF
Control:
Mean age 53.3 
(10.9)
53% VF
ALN*: 10 mg + 
500 mg Calcium 
Control: 500 mg 
Calcium + 1 µg 
alfacalcidiol
- Open-label
- Radiologists 
reading vertebral 
x-rays blinded to 
intervention
-Method of 
randomization 
unclear
16/134 (11.9%)
*ALN, alendronate (daily dose)
\dagBMD, bone mineral density measurement by dual X-ray absorptiometry, compared to young adult male peak bone mass
\ddagSD, Standard deviationBMC Musculoskeletal Disorders 2005, 6:39 http://www.biomedcentral.com/1471-2474/6/39
Page 6 of 8
(page number not for citation purposes)
whom prior information was derived, were similar to
those observed in men. The precision of our estimate was
however slightly improved using a Bayesian approach for
the outcome of non-vertebral fractures as seen by the
slightly narrower credibility interval than confidence
interval for that outcome. Credibility intervals can be nar-
rower using a Bayesian approach than confidence inter-
vals obtained using a frequentist approach because of
additional data provided by the priors [9].
Given that the results of our Bayesian and frequentist
meta-analyses were similar, was there any advantage to
the Bayesian approach? The basic question posed using a
frequentist approach is how likely are the data given the
null hypothesis? In contrast, the question posed from a
Bayesian perspective is, how likely is the odds ratio, given
the data [8]? Furthermore, the interpretation of a tradi-
tional 95% confidence interval is that given a long series
of such intervals, 95% of them should contain the true
value of the odds ratio [9]. In contrast, in interpreting a
95% credibility interval, there is a 95% probability that
the true value of the parameter lies within this interval [9].
Thus, the clinical question posed and the interpretation of
the probability interval, are more clinically intuitive from
a Bayesian perspective. Moreover, the Bayesian approach
allowed the flexibility to incorporate clinically relevant
evidence from trials in women in this meta-analysis of
alendronate treatment in men.
In the future, more trials of active osteoporotic therapies
and their effects on fracture outcomes need to be per-
formed in both genders.
Conclusion
We conclude that alendronate (10 mg daily) decreases the
risk of vertebral fractures in men with low bone mass or
fractures, but there is currently insufficient evidence to
prove a significant effect on non-vertebral fractures in this
population. The paucity of osteoporosis therapy trials in
men as well as the relative infrequency of non-vertebral
Pooled random effects meta-analyses of vertebral and non-vertebral fracture outcomes with alendronate treatment (frequen- tist models) Figure 2
Pooled random effects meta-analyses of vertebral and non-vertebral fracture outcomes with alendronate 
treatment (frequentist models). OR, Odds Ratio; 95% CI Random, 95% confidence interval using a frequentist random 
effects model for pooling the data from studiesBMC Musculoskeletal Disorders 2005, 6:39 http://www.biomedcentral.com/1471-2474/6/39
Page 7 of 8
(page number not for citation purposes)
fractures in the control groups may have restricted our sta-
tistical power to detect a significant reduction of non-ver-
tebral fractures. Of note, the relative risk of vertebral
fracture in alendronate-treated men was similar to that
previously observed in a meta-analysis of data from post-
menopausal women [2].
Appendix
Electronic search strategy for potentially relevant studies
For Medline and Medline-in-Process (1966 to May 24,
2004), Cochrane Central Register of Controlled Trials
(1800 to May 24, 2004): "alendronate" or "fosamax" -
restricted to adult male humans (age ≥  19 years), clinical
trials, controlled clinical trials, and randomized control-
led trials.
For Embase 1996 to May 24, 2004: "alendronate" or
"fosamax" AND "male" or "men"- restricted to adult male
humans (age ≥  19 years), clinical trials, controlled clinical
trials, and randomized controlled trials.
For PubMed (up to May 24, 2004): name and initials of
authors of included studies AND "alendronate" or
"fosamax"
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